Epiduo adapalene/benzoyl peroxide: Post-marketing study data

The double-blind, post-marketing ACCESS trial in 459 patients showed that topical once-daily Epiduo plus 100 mg once-daily oral doxycycline met the primary endpoint of reducing total lesion count at week 12 vs. gel vehicles plus doxycycline (64% vs. 41%, p<0.001). Epiduo plus doxycycline also met the secondary endpoints of reducing inflammatory (72% vs. 48%) and non-inflammatory (61% vs. 40%) lesion counts at week 12 vs. gel vehicle plus doxycycline (p<0.001 for both). The differences between treatment groups reached significance as early as week 2 on all three lesion count endpoints. ...